CD8A and melanoma: In humans with melanoma, when ISCOMATRIX adjuvanted NY-ESO-1 protein was given as a vaccine, vaccinees developed high frequencies of long lasting specific CD8+T cell responses in vivo on booster immunization to a wide array of NY-ESO-1 peptides [21].